

AMENDMENT

In the Claims

This listing of claims will replace all prior versions and listings of claims.

- 1-26. (Canceled)
27. (Previously Presented) A method for delivery of one or more cytokines comprising administering to a human or animal a composition comprising one or more cytokines and a target molecule admixed with or bound to a colloidal metal.
28. (Previously Presented) The method of Claim 27, wherein the one or more cytokines are selected from the group consisting of Interleukin-1a ("IL-1 α "), Interleukin-1B ("IL-1 β "), Interleukin-2 ("IL-2"), Interleukin-3 ("IL-3"), Interleukin-4 ("IL-4"), Interleukin-5 ("IL-5"), Interleukin-6 ("IL-6"), Interleukin-7 ("IL-7"), Interleukin-8 ("IL-8"), Interleukin-9 ("IL-9"), Interleukin-10 ("IL-10"), Interleukin-11 ("IL-11"), Interleukin-12 ("IL-12"), Interleukin-13 ("IL-13"), Type I Interferon, Type II Interferon, Migration Inhibition Factor, Granulocyte-Macrophage Colony-Stimulating Factor ("CSF"), Monocyte-Macrophage CSF, and Granulocyte CSF.
29. (Canceled)
30. (Canceled)
31. (Currently Amended) The method of Claim 27, wherein the target molecule is selected from the group consisting of Tumor Necrosis Factor ("TNF α "), Transforming Growth Factor- β ("TGF β "), Migration Inhibition Factor, vascular endothelial ~~epithelial~~ growth

factor (“VEGF”), receptor proteins, glucose, glycogen, phospholipids, monoclonal and/or polyclonal antibodies, cancer cell specific antigen, and transforming growth factor alpha (“TGF α ”).

32-39. (Canceled)

40. (Previously Presented) The method of claim 31, wherein the target molecule is a cancer cell specific antigen.

41. (Previously Presented) The method of claim 40, wherein the cancer cell specific antigen is MART, MAGE, or BAGE.

42. (Previously Presented) The method of claim 31, wherein the target molecule is a polyclonal or monoclonal antibody.

43-48. (Canceled)